Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | SUNEVO: sunitinib/evofosfamide for metastatic pancreatic NETs

Enrique Grande • 30 Oct 2019
ESMO 2019
Neuroendocrine Tumor Evofosfamide Sunitinib
GETNE-1408

Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the SUNEVO (GETNE-1408; NCT02402062) Phase II trial of sunitinib plus evofosfamide for G1/G2 metastatic pancreatic neuroendocrine tumors naïve for systemic treatment. While this failed to demonstrate activity in terms of tumor shrinkage, it revealed useful information. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Enrique Grande

1:39
Emerging biomarkers of ADC response and toxicity in urothelial carcinoma
Enrique Grande • 25 Jan 2024
2:30
The future of antibody-drug conjugates in urothelial cancer
Enrique Grande • 25 Jan 2024
1:58
What’s next for antibody drug conjugates in urothelial carcinoma?
Enrique Grande • 25 Jan 2024
1:23
CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma
Enrique Grande • 25 Jan 2024

Related Videos

1:58
What’s next for antibody drug conjugates in urothelial carcinoma?
Enrique Grande • 25 Jan 2024
1:23
CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma
Enrique Grande • 25 Jan 2024
0:38
Precision medicine for neuroendocrine carcinomas: NABNEC study insights
Lorraine A. Chantrill • 18 Jan 2024
1:05
NABNEC: nab-paclitaxel + carboplatin as 1L treatment of gastrointestinal neuroendocrine carcinomas
Lorraine A. Chantrill • 19 Jan 2024
The content of VJOncology is intended for healthcare professionals